Acute Myelomonocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Myelomonocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Myelomonocytic Leukemia?
A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.
What are the alternative names for Acute Myelomonocytic Leukemia?
  • Acute myelomonocytic leukemia
  • Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML M4
  • AML-M4
  • AMMoL
  • Acute myeloblastic leukemia type 4
  • AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
  • Acute myelomonocytic leukemia
  • CBFB-MYH11
Who are the top Acute Myelomonocytic Leukemia Local Doctors?
Robert J. Soiffer
Experienced in Acute Myelomonocytic Leukemia
Dr. Robert J. Soiffer
Oncology | Hematology
Experienced in Acute Myelomonocytic Leukemia
Dr. Robert J. Soiffer
Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

20 Prospect St, Suite 2, 
Milford, MA 
 (0.6 mi)
508-473-1190
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Soiffer is an Oncologist and a Hematologist in Milford, Massachusetts. Dr. Soiffer and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft. Dr. Soiffer is currently accepting new patients.

Experienced in Acute Myelomonocytic Leukemia
Dr. Jan Cerny
Hematology Oncology | Hematology | Oncology
Experienced in Acute Myelomonocytic Leukemia
Dr. Jan Cerny
Hematology Oncology | Hematology | Oncology

Umass Memorial Medical Group Inc

55 Lake Ave N, 
Worcester, MA 
 (15.5 mi)
508-334-1000
Experience:
26+ years
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Jan Cerny is a Hematologist Oncology specialist and a Hematologist in Worcester, Massachusetts. Dr. Cerny has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Cerny is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Acute Myelomonocytic Leukemia
Dr. Muthalagu Ramanathan
Hematology Oncology | Hematology | Oncology
Experienced in Acute Myelomonocytic Leukemia
Dr. Muthalagu Ramanathan
Hematology Oncology | Hematology | Oncology

Umass Memorial Medical Group Inc

55 Lake Ave N, 
Worcester, MA 
 (15.5 mi)
508-334-1000
Languages Spoken:
English, Tamil
Accepting New Patients
Offers Telehealth

Muthalagu Ramanathan is a Hematologist Oncology specialist and a Hematologist in Worcester, Massachusetts. Dr. Ramanathan and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ramanathan is currently accepting new patients.

View All Doctors
What are the latest Acute Myelomonocytic Leukemia Clinical Trials?
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Who is this study for: Adult patients with Acute Myeloid Leukemia or Bilineage Leukemia
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Enasidenib
Study Phase: Phase 2

Summary: This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2 dose (RP2D) of this combination. The study will begin as a Phase 1 Dose Escalation study to determine the RP2D and then will transition to a Phase 2 Dose Expansion study to assess the efficacy of the...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center